Reciprocal Regulation of Sulfite Oxidation and Nitrite Reduction By
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Human Sulfite Oxidase R160Q: Identification of the Mutation in a Sulfite Oxidase-Deficient Patient and Expression and Characterization of the Mutant Enzyme
Proc. Natl. Acad. Sci. USA Vol. 95, pp. 6394–6398, May 1998 Medical Sciences Human sulfite oxidase R160Q: Identification of the mutation in a sulfite oxidase-deficient patient and expression and characterization of the mutant enzyme ROBERT M. GARRETT*†,JEAN L. JOHNSON*, TYLER N. GRAF*, ANNETTE FEIGENBAUM‡, AND K. V. RAJAGOPALAN*§ *Department of Biochemistry, Duke University Medical Center, Durham, NC 27710; and ‡Department of Genetics, The Hospital for Sick Children and University of Toronto, 555 University Avenue, Toronto, ON, Canada M5G 1X8 Edited by Irwin Fridovich, Duke University Medical Center, Durham, NC, and approved March 19, 1998 (received for review February 17, 1998) ABSTRACT Sulfite oxidase catalyzes the terminal reac- tion in the degradation of sulfur amino acids. Genetic defi- ciency of sulfite oxidase results in neurological abnormalities and often leads to death at an early age. The mutation in the sulfite oxidase gene responsible for sulfite oxidase deficiency in a 5-year-old girl was identified by sequence analysis of cDNA obtained from fibroblast mRNA to be a guanine to adenine transition at nucleotide 479 resulting in the amino acid substitution of Arg-160 to Gln. Recombinant protein containing the R160Q mutation was expressed in Escherichia coli, purified, and characterized. The mutant protein con- tained its full complement of molybdenum and heme, but exhibited 2% of native activity under standard assay condi- tions. Absorption spectroscopy of the isolated molybdenum domains of native sulfite oxidase and of the R160Q mutant showed significant differences in the 480- and 350-nm absorp- tion bands, suggestive of altered geometry at the molybdenum center. -
Cytochrome C Nitrite Reductase (Ccnir) Does Not Disproportionate Hydroxylamine to Ammonia and Nitrite, Despite a Strongly Favorable Driving Force
Marquette University e-Publications@Marquette Physics Faculty Research and Publications Physics, Department of 4-2014 Shewanella oneidensis Cytochrome c Nitrite Reductase (ccNiR) Does Not Disproportionate Hydroxylamine to Ammonia and Nitrite, Despite a Strongly Favorable Driving Force Matthew Youngblut University of Wisconsin - Milwaukee Daniel J. Pauly University of Wisconsin - Milwaukee Natalia Stein University of Wisconsin - Milwaukee Daniel Walters University of Wisconsin - Milwaukee John A. Conrad University of Wisconsin - Milwaukee See next page for additional authors Follow this and additional works at: https://epublications.marquette.edu/physics_fac Part of the Physics Commons Recommended Citation Youngblut, Matthew; Pauly, Daniel J.; Stein, Natalia; Walters, Daniel; Conrad, John A.; Moran, Graham R.; Bennett, Brian; and Pacheco, A. Andrew, "Shewanella oneidensis Cytochrome c Nitrite Reductase (ccNiR) Does Not Disproportionate Hydroxylamine to Ammonia and Nitrite, Despite a Strongly Favorable Driving Force" (2014). Physics Faculty Research and Publications. 7. https://epublications.marquette.edu/physics_fac/7 Authors Matthew Youngblut, Daniel J. Pauly, Natalia Stein, Daniel Walters, John A. Conrad, Graham R. Moran, Brian Bennett, and A. Andrew Pacheco This article is available at e-Publications@Marquette: https://epublications.marquette.edu/physics_fac/7 Marquette University e-Publications@Marquette Physics Faculty Research and Publications/College of Arts and Sciences This paper is NOT THE PUBLISHED VERSION; but the author’s final, peer-reviewed manuscript. The published version may be accessed by following the link in the citation below. Biochemistry, Vol. 53, No. 13 (8 April 2014): 2136–2144. DOI. This article is © American Chemical Society Publications and permission has been granted for this version to appear in e- Publications@Marquette. American Chemical Society Publications does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express permission from American Chemical Society Publications. -
Amino Acid Disorders
471 Review Article on Inborn Errors of Metabolism Page 1 of 10 Amino acid disorders Ermal Aliu1, Shibani Kanungo2, Georgianne L. Arnold1 1Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA Contributions: (I) Conception and design: S Kanungo, GL Arnold; (II) Administrative support: S Kanungo; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: E Aliu, GL Arnold; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Georgianne L. Arnold, MD. UPMC Children’s Hospital of Pittsburgh, 4401 Penn Avenue, Suite 1200, Pittsburgh, PA 15224, USA. Email: [email protected]. Abstract: Amino acids serve as key building blocks and as an energy source for cell repair, survival, regeneration and growth. Each amino acid has an amino group, a carboxylic acid, and a unique carbon structure. Human utilize 21 different amino acids; most of these can be synthesized endogenously, but 9 are “essential” in that they must be ingested in the diet. In addition to their role as building blocks of protein, amino acids are key energy source (ketogenic, glucogenic or both), are building blocks of Kreb’s (aka TCA) cycle intermediates and other metabolites, and recycled as needed. A metabolic defect in the metabolism of tyrosine (homogentisic acid oxidase deficiency) historically defined Archibald Garrod as key architect in linking biochemistry, genetics and medicine and creation of the term ‘Inborn Error of Metabolism’ (IEM). The key concept of a single gene defect leading to a single enzyme dysfunction, leading to “intoxication” with a precursor in the metabolic pathway was vital to linking genetics and metabolic disorders and developing screening and treatment approaches as described in other chapters in this issue. -
Molybdenum Cofactor and Sulfite Oxidase Deficiency Jochen Reiss* Institute of Human Genetics, University Medicine Göttingen, Germany
ics: O om pe ol n b A a c t c e e M s s Reiss, Metabolomics (Los Angel) 2016, 6:3 Metabolomics: Open Access DOI: 10.4172/2153-0769.1000184 ISSN: 2153-0769 Research Article Open Access Molybdenum Cofactor and Sulfite Oxidase Deficiency Jochen Reiss* Institute of Human Genetics, University Medicine Göttingen, Germany Abstract A universal molybdenum-containing cofactor is necessary for the activity of all eukaryotic molybdoenzymes. In humans four such enzymes are known: Sulfite oxidase, xanthine oxidoreductase, aldehyde oxidase and a mitochondrial amidoxime reducing component. Of these, sulfite oxidase is the most important and clinically relevant one. Mutations in the genes MOCS1, MOCS2 or GPHN - all encoding cofactor biosynthesis proteins - lead to molybdenum cofactor deficiency type A, B or C, respectively. All three types plus mutations in the SUOX gene responsible for isolated sulfite oxidase deficiency lead to progressive neurological disease which untreated in most cases leads to death in early childhood. Currently, only for type A of the cofactor deficiency an experimental treatment is available. Introduction combination with SUOX deficiency. Elevated xanthine and lowered uric acid concentrations in the urine are used to differentiate this Isolated sulfite oxidase deficiency (MIM#606887) is an autosomal combined form from the isolated SUOX deficiency. Rarely and only in recessive inherited disease caused by mutations in the sulfite oxidase cases of isolated XOR deficiency xanthine stones have been described (SUOX) gene [1]. Sulfite oxidase is localized in the mitochondrial as a cause of renal failure. Otherwise, isolated XOR deficiency often intermembrane space, where it catalyzes the oxidation of sulfite to goes unnoticed. -
The Noncanonical Pathway for in Vivo Nitric Oxide Generation: the Nitrate-Nitrite-Nitric Oxide Pathway
1521-0081/72/3/692–766$35.00 https://doi.org/10.1124/pr.120.019240 PHARMACOLOGICAL REVIEWS Pharmacol Rev 72:692–766, July 2020 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: CHRISTOPHER J. GARLAND The Noncanonical Pathway for In Vivo Nitric Oxide Generation: The Nitrate-Nitrite-Nitric Oxide Pathway V. Kapil, R. S. Khambata, D. A. Jones, K. Rathod, C. Primus, G. Massimo, J. M. Fukuto, and A. Ahluwalia William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London, London, United Kingdom (V.K., R.S.K., D.A.J., K.R., C.P., G.M., A.A.) and Department of Chemistry, Sonoma State University, Rohnert Park, California (J.M.F.) Abstract ...................................................................................694 Significance Statement. ..................................................................694 I. Introduction . ..............................................................................694 A. Chemistry of ·NO and Its Metabolism to Nitrite and Nitrate . .........................695 II. Inorganic Nitrite and Nitrate . ............................................................697 A. Historical Uses of Inorganic Nitrite.....................................................697 B. Historical Uses of Inorganic Nitrate ....................................................698 III. Sources and Pharmacokinetics of Nitrate . ................................................698 -
Protein Disulfide Isomerase May Facilitate the Efflux
Redox Biology 1 (2013) 373–380 Contents lists available at SciVerse ScienceDirect Redox Biology journal homepage: www.elsevier.com/locate/redox Protein disulfide isomerase may facilitate the efflux of nitrite derived S-nitrosothiols from red blood cells$ Vasantha Madhuri Kallakunta a, Anny Slama-Schwok b, Bulent Mutus a,n a Department of Chemistry and Biochemistry, University of Windsor, Windsor, Ontario, Canada N9B 3P4 b INRA UR892, Domaine de Vilvert, 78352 Jouy-en-Josas, France article info abstract Article history: Protein disulfide isomerase (PDI) is an abundant protein primarily found in the endoplasmic reticulum Received 20 June 2013 and also secreted into the blood by a variety of vascular cells. The evidence obtained here, suggests that Received in revised form PDI could directly participate in the efflux of NO+ from red blood cells (RBC). PDI was detected both in 8 July 2013 RBC membranes and in the cytosol. PDI was S-nitrosylated when RBCs were exposed to nitrite under Accepted 9 July 2013 ∼50% oxygen saturation but not under ∼100% oxygen saturation. Furthermore, it was observed that hemoglobin (Hb) could promote PDI S-nitrosylation in the presence of ∼600 nM nitrite. In addition, three Keywords: lines of evidence were obtained for PDI–Hb interactions: (1) Hb co-immunoprecipitated with PDI; (2) Hb Nitrite reductase quenched the intrinsic PDI fluorescence in a saturable manner; and (3) Hb–Fe(II)–NO absorption S-nitrosohemoglobin spectrum decreased in a [PDI]-dependent manner. Finally, PDI was detected on the surface RBC under Hypoxic vasodilation ∼100% oxygen saturation and released as soluble under ∼50% oxygen saturation. -
Mechanistic Study of Cysteine Dioxygenase, a Non-Heme
MECHANISTIC STUDY OF CYSTEINE DIOXYGENASE, A NON-HEME MONONUCLEAR IRON ENZYME by WEI LI Presented to the Faculty of the Graduate School of The University of Texas at Arlington in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY THE UNIVERSITY OF TEXAS AT ARLINGTON August 2014 Copyright © by Student Name Wei Li All Rights Reserved Acknowledgements I would like to thank Dr. Pierce for your mentoring, guidance and patience over the five years. I cannot go all the way through this without your help. Your intelligence and determination has been and will always be an example for me. I would like to thank my committee members Dr. Dias, Dr. Heo and Dr. Jonhson- Winters for the directions and invaluable advice. I also would like to thank all my lab mates, Josh, Bishnu ,Andra, Priyanka, Eleanor, you all helped me so I could finish my projects. I would like to thank the Department of Chemistry and Biochemistry for the help with my academic and career. At Last, I would like to thank my lovely wife and beautiful daughter who made my life meaningful and full of joy. July 11, 2014 iii Abstract MECHANISTIC STUDY OF CYSTEINE DIOXYGENASE A NON-HEME MONONUCLEAR IRON ENZYME Wei Li, PhD The University of Texas at Arlington, 2014 Supervising Professor: Brad Pierce Cysteine dioxygenase (CDO) is an non-heme mononuclear iron enzymes that catalyzes the O2-dependent oxidation of L-cysteine (Cys) to produce cysteine sulfinic acid (CSA). CDO controls cysteine levels in cells and is a potential drug target for some diseases such as Parkinson’s and Alzhermer’s. -
Structural Enzymology of Sulfide Oxidation by Persulfide Dioxygenase and Rhodanese
Structural Enzymology of Sulfide Oxidation by Persulfide Dioxygenase and Rhodanese by Nicole A. Motl A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Biological Chemistry) in the University of Michigan 2017 Doctoral Committee Professor Ruma Banerjee, Chair Assistant Professor Uhn-Soo Cho Professor Nicolai Lehnert Professor Stephen W. Ragsdale Professor Janet L. Smith Nicole A. Motl [email protected] ORCID iD: 0000-0001-6009-2988 © Nicole A. Motl 2017 ACKNOWLEDGEMENTS I would like to take this opportunity to acknowledge the many people who have provided me with guidance and support during my doctoral studies. First I would like to express my appreciation and gratitude to my advisor Dr. Ruma Banerjee for the mentorship, guidance, support and encouragement she has provided. I would like to thank my committee members Dr. Uhn-Soo Cho, Dr. Nicolai Lehnert, Dr. Stephen Ragsdale and Dr. Janet Smith for their advice, assistance and support. I would like to thank Dr. Janet Smith and members of Dr. Smith’s lab, especially Meredith Skiba, for sharing their expertise in crystallography. I would like to thank Dr. Omer Kabil for his help, suggestions and discussions in various aspects of my study. I would also like to thank members of Dr. Banerjee’s lab for their suggestions and discussions. Additionally, I would like to thank my friends and family for their support. ii TABLE OF CONTENTS ACKNOWLEDGEMENTS ii LIST OF TABLES viii LIST OF FIGURES ix ABBREVIATIONS xi ABSTRACT xii CHAPTER I. Introduction: -
Diseases Catalogue
Diseases catalogue AA Disorders of amino acid metabolism OMIM Group of disorders affecting genes that codify proteins involved in the catabolism of amino acids or in the functional maintenance of the different coenzymes. AA Alkaptonuria: homogentisate dioxygenase deficiency 203500 AA Phenylketonuria: phenylalanine hydroxylase (PAH) 261600 AA Defects of tetrahydrobiopterine (BH 4) metabolism: AA 6-Piruvoyl-tetrahydropterin synthase deficiency (PTS) 261640 AA Dihydropteridine reductase deficiency (DHPR) 261630 AA Pterin-carbinolamine dehydratase 126090 AA GTP cyclohydrolase I deficiency (GCH1) (autosomal recessive) 233910 AA GTP cyclohydrolase I deficiency (GCH1) (autosomal dominant): Segawa syndrome 600225 AA Sepiapterin reductase deficiency (SPR) 182125 AA Defects of sulfur amino acid metabolism: AA N(5,10)-methylene-tetrahydrofolate reductase deficiency (MTHFR) 236250 AA Homocystinuria due to cystathionine beta-synthase deficiency (CBS) 236200 AA Methionine adenosyltransferase deficiency 250850 AA Methionine synthase deficiency (MTR, cblG) 250940 AA Methionine synthase reductase deficiency; (MTRR, CblE) 236270 AA Sulfite oxidase deficiency 272300 AA Molybdenum cofactor deficiency: combined deficiency of sulfite oxidase and xanthine oxidase 252150 AA S-adenosylhomocysteine hydrolase deficiency 180960 AA Cystathioninuria 219500 AA Hyperhomocysteinemia 603174 AA Defects of gamma-glutathione cycle: glutathione synthetase deficiency (5-oxo-prolinuria) 266130 AA Defects of histidine metabolism: Histidinemia 235800 AA Defects of lysine and -
Higher Susceptibility of Cerebral Cortex and Striatum to Sulfite Neurotoxicity
Biochimica et Biophysica Acta 1862 (2016) 2063–2074 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbadis Higher susceptibility of cerebral cortex and striatum to sulfite neurotoxicity in sulfite oxidase-deficient rats Mateus Grings a, Alana Pimentel Moura a, Belisa Parmeggiani a, Marcela Moreira Motta a, Rafael Mello Boldrini a, Pauline Maciel August a, Cristiane Matté a,b, Angela T.S. Wyse a,b, Moacir Wajner a,b,c, Guilhian Leipnitz a,b,⁎ a Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil b Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600-Anexo, CEP 90035-003, Porto Alegre, RS, Brazil c Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, CEP 90035-903, Porto Alegre, RS, Brazil article info abstract Article history: Patients affected by sulfite oxidase (SO) deficiency present severe seizures early in infancy and progressive Received 14 May 2016 neurological damage, as well as tissue accumulation of sulfite, thiosulfate and S-sulfocysteine. Since the Received in revised form 27 July 2016 pathomechanisms involved in the neuropathology of SO deficiency are still poorly established, we evaluated Accepted 9 August 2016 the effects of sulfite on redox homeostasis and bioenergetics in cerebral cortex, striatum, cerebellum and Available online 12 August 2016 hippocampus of rats with chemically induced SO deficiency. The deficiency was induced in 21-day-old rats by adding 200 ppm of tungsten, a molybdenum competitor, in their drinking water for 9 weeks. -
The Requirement of Inorganic Fe-S Clusters for the Biosynthesis of the Organometallic Molybdenum Cofactor
inorganics Review The Requirement of Inorganic Fe-S Clusters for the Biosynthesis of the Organometallic Molybdenum Cofactor Ralf R. Mendel 1, Thomas W. Hercher 1, Arkadiusz Zupok 2, Muhammad A. Hasnat 2 and Silke Leimkühler 2,* 1 Institute of Plant Biology, Braunschweig University of Technology, Humboldtstr. 1, 38106 Braunschweig, Germany; [email protected] (R.R.M.); [email protected] (T.W.H.) 2 Department of Molecular Enzymology, Institute of Biochemistry and Biology, University of Potsdam, Karl-Liebknecht-Str. 24-25, 14476 Potsdam, Germany; [email protected] (A.Z.); [email protected] (M.A.H.) * Correspondence: [email protected]; Tel.: +49-331-977-5603; Fax: +49-331-977-5128 Received: 18 June 2020; Accepted: 14 July 2020; Published: 16 July 2020 Abstract: Iron-sulfur (Fe-S) clusters are essential protein cofactors. In enzymes, they are present either in the rhombic [2Fe-2S] or the cubic [4Fe-4S] form, where they are involved in catalysis and electron transfer and in the biosynthesis of metal-containing prosthetic groups like the molybdenum cofactor (Moco). Here, we give an overview of the assembly of Fe-S clusters in bacteria and humans and present their connection to the Moco biosynthesis pathway. In all organisms, Fe-S cluster assembly starts with the abstraction of sulfur from l-cysteine and its transfer to a scaffold protein. After formation, Fe-S clusters are transferred to carrier proteins that insert them into recipient apo-proteins. In eukaryotes like humans and plants, Fe-S cluster assembly takes place both in mitochondria and in the cytosol. -
Sulfite Oxidase (Ec 1.8.3.1)
Enzymatic Assay of SULFITE OXIDASE (EC 1.8.3.1) PRINCIPLE: Sulfite Oxidase Sulfite + O2 + H2O + Cyt c (Oxidized) > Sulfate + Cyt c (Reduced) + H2O2 Abbreviations used: Cyt c = Cytochrome c CONDITIONS: T = 25°C, pH = 8.5, A550nm, Light path = 1 cm METHOD: Continuous Spectrophotometric Rate Determination REAGENTS: A. 100 mM Tris HCl Buffer, pH 8.5 at 25°C (Prepare 500 ml in deionized water using Trizma Base, Prod. No. T-1503. Adjust to pH 8.5 at 25°C with 1 M HCl.) B. 33 mM Sodium Sulfite Solution (Prepare 10 ml in Reagent A using Sodium Sulfite, Anhydrous, Prod. No. S-0505.) C. 2 mM Cytochrome c (Prepare 10 ml in Reagent A using Cytochrome c, from Chicken Heart, Prod. No C-0761.) D. Sulfite Oxidase Enzyme Solution (Immediately before use, prepare a solution containing 0.05 - 0.07 units/ml of Sulfite Oxidase in cold Reagent A.) SPSULF01.001 Page 1 of 3 Revised: 01/21/94 Enzymatic Assay of SULFITE OXIDASE (EC 1.8.3.1) PROCEDURE: Pipette (in milliliters) the following reagents into suitable cuvettes: Test Blank Reagent A (Buffer) 2.77 2.77 Reagent B (Sodium Sulfite) 0.03 ------ Reagent C (Cytochrome c) 0.10 0.10 Deionized Water ------ 0.03 Equilibrate to 25°C. Monitor the A550nm until constant, using a suitably thermostatted spectrophotometer. Then add: Reagent D (Enzyme Solution) 0.10 0.10 Immediately mix by inversion and record the increase in A550nm for approximately 5 minutes. Obtain the ∆A550nm/minute using the maximum linear rate for both the Test and Blank.